ADMA Biologics Inc. (NASDAQ: ADMA) is -29.25% lower on its value in year-to-date trading and has touched a low of $1.45 and a high of $5.48 in the current 52-week trading range. The ADMA stock was last observed hovering at around $2.83 in the recent trading session, with the current gains setting it 0.04% off its average median price target of $9.50 for the next 12 months. It is also 80.87% off the consensus price target high of $15.00 offered by 6 analysts, but current levels are 52.17% higher than the price target low of $6.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $2.87, the stock is -1.95% and -0.62% below its SMA20 and SMA50 respectively. However, with a current trading volume of 0.6 million and changing 1.41% at the moment leaves the stock -19.47% off its SMA200. ADMA registered -27.44% loss for a year compared to 6-month loss of -35.68%. The firm has a 50-day simple moving average (SMA 50) of $2.9495 and a 200-day simple moving average (SMA200) of $3.1712.
The stock witnessed a -2.41% gain in the last 1 month and extending the period to 3 months gives it a 3.66%, and is -2.08% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.03% over the week and 5.48% over the month.
ADMA Biologics Inc. (ADMA) has around 313 employees, a market worth around $247.79M and $36.00M in sales. Distance from 52-week low is 97.93% and -47.67% from its 52-week high.
ADMA Biologics Inc. (ADMA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ADMA Biologics Inc. (ADMA) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ADMA Biologics Inc. is expected to release its quarterly report on 08/07/2020 and quarterly earnings per share for the current quarter are estimated at -$0.16 with sales reaching $10.58M over the same period.The EPS is expected to grow by 38.90% this year, but quarterly earnings will post 73.10% year-over-year. Quarterly sales are estimated to grow 61.30% in year-over-year returns.
ADMA Biologics Inc. (ADMA) Top Institutional Holders
125 institutions hold shares in ADMA Biologics Inc. (ADMA), with 6.35M shares held by insiders accounting for 7.35% while institutional investors hold 51.71% of the company’s shares. The shares outstanding are 73.78M, and float is at 62.78M with Short Float at 15.22%. Institutions hold 47.91% of the Float.
The top institutional shareholder in the company is Perceptive Advisors Llc with over 16.58 million shares valued at $47.76 million. The investor’s holdings represent 19.21% of the ADMA Shares outstanding. As of Mar 30, 2020, the second largest holder is Blackrock Inc. with 5.3 million shares valued at $15.26 million to account for 6.14% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.56 million shares representing 4.12% and valued at over $10.25 million, while Consonance Capital Management LP holds 3.92% of the shares totaling 3.38 million with a market value of $9.74 million.
ADMA Biologics Inc. (ADMA) Insider Activity
A total of 18 insider transactions have happened at ADMA Biologics Inc. (ADMA) in the last six months, with sales accounting for 0 and purchases happening 18 times. The most recent transaction is an insider purchase by PERCEPTIVE ADVISORS LLC, the company’s 10% Owner. SEC filings show that PERCEPTIVE ADVISORS LLC bought 500,000 shares of the company’s common stock on Mar 19 at a price of $2.10 per share for a total of $1.05 million. Following the purchase, the insider now owns 16.58 million shares.
ADMA Biologics Inc. disclosed in a document filed with the SEC on Feb 11 that PERCEPTIVE ADVISORS LLC (10% Owner) bought a total of 4,563,700 shares of the company’s common stock. The trade occurred on Feb 11 and was made at $3.50 per share for $15.97 million. Following the transaction, the insider now directly holds 16.08 million shares of the ADMA stock.
Still, SEC filings show that on Feb 11, Guiheen Lawrence P. (Director) acquired 20,000 shares at an average price of $3.50 for $70000.0. The insider now directly holds 70,000 shares of ADMA Biologics Inc. (ADMA).
ADMA Biologics Inc. (ADMA): Who are the competitors?
The company’s main competitors (and peers) include CEL-SCI Corporation (CVM) that is trading 89.15% up over the past 12 months. Short interest in the company’s stock has fallen -5.1% from the last report on May 14, 2020 to stand at a total of 9.68 million short shares sold with a short interest ratio of 2.72.